Semaglutide

Semaglutide is a Glucagon-Like Peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection (Ozempic®, Wegovy®) or a daily oral tablet (Rybelsus®). It is approved to improve glycemic control in adults with Type 2 Diabetes and for chronic weight management in adults and adolescents with obesity or overweight, with significant proven benefits for cardiovascular and kidney risk reduction.